ICU Delirium Management and Screening Guidelines
Overview and Definition of Delirium
- Core Definition: Delirium is an acute and fluctuating alteration in attention and awareness that develops over a short period (hours to days). Its rapid onset mandates an immediate search for an underlying medical condition, organ dysfunction, or medication-related etiology.
- Primary Cardinal Feature: Inattention is the hallmark manifestation of delirium. Patients experience profound difficulty focusing, sustaining focus, or shifting attention. Clinical manifestations include losing track of a conversation, becoming easily distracted, or exhibiting an inability to follow simple commands.
- Associated Cognitive and Neuropsychiatric Features: Patients may demonstrate disorganized thinking, an altered level of consciousness, perceptual disturbances (illusions), or frank hallucinations.
- Differential Diagnosis (Delirium vs. Dementia):
- Delirium: Typically sudden in onset with a characteristically fluctuating course over hours to days.
- Dementia: Characterized by a chronic, insidious, and progressive cognitive decline.
- Co-occurrence: Dementia is a major risk factor for delirium, and both conditions can frequently coexist in the same patient.
- Epidemiology: Delirium occurs in approximately 60% to 80% of mechanically ventilated intensive care unit (ICU) patients.
- Clinical Pearl: A patient who appears quiet, hypoactive, and sleepy may still be severely delirious.
Clinical Subtypes of Delirium
- Hyperactive Delirium:
- Presentation: Marked by psychomotor agitation, restlessness, combativeness, pulling at invasive lines or catheters, and active hallucinations.
- Hypoactive Delirium:
- Presentation: Marked by withdrawal, lethargy, psychomotor slowing, somnolence, or minimal responsiveness.
- Clinical Significance: Hypoactive delirium is the most common subtype and is frequently missed by healthcare providers due to its non-disruptive nature.
- Mixed Subtype Delirium:
- Presentation: Demonstrates a fluctuating course that alternates between hyperactive and hypoactive features.

Risk Factors and Etiologic Triggers
- Baseline Risk Factors (Predisposing Factors):
- Advanced age.
- Baseline cognitive impairment or underlying dementia.
- High severity of acute illness.
- Acute Precipitating Triggers:
- Physiologic/Infectious Stressors: Severe pain, hypoxemia, acute infection, sepsis, and shock.
- Metabolic/Endocrine Disruptions: Electrolyte derangements, blood glucose fluctuations, renal impairment, hepatic dysfunction, and other metabolic derangements.
- Reversible Physiological Contributors: Sleep disruption, prolonged immobility, dehydration, acute urinary retention, and fecal constipation.
- Substance Withdrawal: Acute withdrawal from alcohol, benzodiazepines, or nicotine.
- Environmental/Iatrogenic Factors: Unfamiliar ICU environment, physical restraints, indwelling urinary or vascular catheters, and uncorrected sensory deficits (unaddressed hearing or vision loss).
- Medication-Induced Delirium (Medication Review Protocols):
- Assessment Steps: Systematically evaluate for newly initiated agents, dose escalations, drug accumulation secondary to acute organ failure (renal/hepatic), and sudden drug discontinuation.
- High-Risk Pharmacologic Classes:
- Benzodiazepines (particularly repeated dosing or continuous intravenous infusions).
- Anticholinergic medications (e.g., diphenhydramine, hydroxyzine, oxybutynin).
- Opioids or excessive sedative administration.
- Sedative-hypnotics, central muscle relaxants, systemic corticosteroids, and general polypharmacy.
- Critical Safety Rule: Do not abruptly stop a medication if withdrawal is clinically possible.

Screening and Assessment Protocols: RASS and CAM-ICU
- Screening Sequence: Assessment must proceed by measuring the level of sedation/agitation with the Richmond Agitation-Sedation Scale (RASS) first, followed by the Confusion Assessment Method for the ICU (CAM-ICU).
- Richmond Agitation-Sedation Scale (RASS):
- Purpose: Quantitative assessment of wakefulness, agitation, or depth of sedation.
- Scale Range: Ranges from +4 (combative) down to −5 (unarousable).
- Target/Normal Score: A score of 0 indicates an alert and calm patient.
- Feasibility Check: A patient must be sufficiently awake to be evaluated for delirium. If the RASS score is −4 (deep sedation) or −5 (unarousable), the CAM-ICU cannot be completed, and screening must be deferred until the patient achieves a higher level of arousal.
- Confusion Assessment Method for the ICU (CAM-ICU):
- Purpose: A validated bedside tool designed for rapid screening of delirium in critically ill patients, including non-verbal intubated patients.
- Feature 1: Acute Onset or Fluctuating Course — Evidence of a sudden mental status change from baseline or a fluctuating mental status over the preceding 24 hours.
- Feature 2: Inattention — Evaluated via a auditory/tactile letter recognition test using the 10-letter target word SAVEAHAART. The patient is instructed to squeeze the examiner's hand every time the letter A is spoken. A total of 3 or more errors (squeezing on a non-A letter or failing to squeeze on an A letter) indicates positive inattention.
- Feature 3: Altered Level of Consciousness — Present if the patient's current RASS score is anything other than 0 (e.g., −3, −2, −1, +1, +2, +3, or +4).
- Feature 4: Disorganized Thinking — Demonstrated by incorrect answers to basic logic questions or an inability to execute simple two-step commands.

- Key Diagnostic Rule for CAM-ICU: A CAM-ICU screening is considered positive for delirium if Feature 1 AND Feature 2 are present, combined with EITHER Feature 3 OR Feature 4.
- Screening Frequency: Because hypoactive delirium is easily missed, screening should be conducted at least once daily, with many intensive care units screening every shift.
Secondary Diagnostic Workup
- Baseline Comparison: Establish the patient's pre-morbid mental status by interviewing family members, proxy decision-makers, or primary caregivers.
- Comprehensive Laboratory and Clinical Diagnostic Check:
- Vital signs and continuous pulse oximetry / arterial oxygenation.
- Assessment for active infection or sepsis.
- Point-of-care blood glucose levels.
- Serum electrolytes, blood urea nitrogen (BUN), serum creatinine, and liver function tests.
- Detailed fluid balance evaluation (intake/output monitoring) and screening for acute urinary retention or bowel impaction/constipation.
- Complete medication profile review.
- Targeted Neurologic Examination: Perform a detailed neurological evaluation. Immediate urgent medical evaluation is mandatory if new focal neurological deficits, acute seizure activity, or traumatic injury are detected.
Delirium Management Guidelines and Non-Pharmacologic Care

- Core Management Philosophy: Management must target the underlying underlying etiology of brain dysfunction rather than attempting to treat the CAM-ICU score in isolation. No single pharmacological agent cures delirium.
- Structured Management Sequence:
- Confirm the presence of acute or fluctuating mental status changes using RASS and CAM-ICU.
- Systematically identify and treat all reversible physiological precipitating causes (hypoxemia, systemic infection, unmanaged pain, metabolic derangements, dehydration, urinary retention, constipation, drug withdrawal, and deliriogenic medications).
- Perform continuous daily reassessments of mental status, patient safety, and intervention response while documenting delirium subtype and score trends.
- First-Line Non-Pharmacologic Interventions:
- Reorientation: Provide frequent, calm reorientation using clocks, wall calendars, and patient communication boards.
- Sleep Hygiene Optimization: Establish a regular sleep-wake cycle by promoting daylight exposure and physical activity during daytime hours, while ensuring a dark, quiet environment at night.
- Early Mobilization: Implement early mobility and physical rehabilitation protocols as soon as medically safe, minimizing unnecessary bedrest.
- Sensory Deficit Management: Ensure prompt provision of prescribed eyeglasses and functional hearing aids. Offer familiar personal objects and regular cognitive stimulation.
- Family Engagement: Encourage active family visits and structured bedside participation.
- Invasive Device Reduction: Optimize pain control, correct hydration deficits, and remove unnecessary urinary catheters, central lines, and physical restraints.
- Primary Principle: Primary prevention represents the single most effective overall delirium management strategy.
The ABCDEF Bundle

- A: Assess, prevent, and manage pain.
- B: Both spontaneous awakening trials (SAT) and spontaneous breathing trials (SBT).
- C: Choice of analgesia and sedation (prioritizing non-benzodiazepine sedatives).
- D: Delirium: assess, prevent, and manage.
- E: Early exercise and mobility.
- F: Family engagement and empowerment.
Pharmacologic Interventions and Clinical Guidelines
- Antipsychotic Guidelines (SCCM PADIS Guidelines & 2025 Focused Update):
- Routine Use Update: The 2025 focused update makes no recommendation for or against the routine use of antipsychotics compared to usual care for delirium treatment. Evidence remains uncertain, as clinical trials fail to demonstrate consistent reductions in delirium duration, duration of mechanical ventilation, ICU length of stay, or overall hospital mortality.
- Restricted Indication: A short course of antipsychotic medication may be considered strictly when severe psychomotor agitation causes immediate physical danger to the patient or staff, or directly impedes essential medical care—and only after reversible causes and non-pharmacologic interventions have been implemented.

- Antipsychotic Agents and Monitoring Protocols:
- Representative Antipsychotics: Haloperidol, Quetiapine, Olanzapine, Ziprasidone.
- Mandatory Safety Monitoring:
- Serial baseline and follow-up 12-lead ECGs to monitor QTc interval duration.
- Serum potassium and magnesium concentrations.
- Extrapyramidal symptoms (EPS).
- Excessive sedation levels.
- Orthostatic hypotension.
- Drug-drug interactions.
- Administrative Requirement: If an antipsychotic is initiated, explicitly document the underlying clinical indication and perform daily evaluations to assess for prompt medication discontinuation.
- Dexmedetomidine Protocol in the ICU:
- Specific Indication: Suggested for mechanically ventilated adult ICU patients when agitation arising from delirium directly prevents successful ventilator weaning or extubation (conditional recommendation based on low-quality evidence).
- Clinical Advantages: Delivers cooperative sedation with a significantly lower risk of precipitating or worsening delirium compared to benzodiazepines.
- Adverse Effects & Safety Monitoring: Monitor heart rate and blood pressure continuously. The primary adverse effects are symptomatic bradycardia and hypotension.
- Implementation Rule: Dexmedetomidine serves as an adjunctive sedative option and does not replace primary cause identification or full implementation of the ABCDEF bundle.
Clinical Escalation and Care Transitions
- Urgent Clinical Escalation Criteria: Immediate escalation and rapid neurological/medical evaluation are required if the patient exhibits:
- New focal neurological deficits.
- Acute seizure activity.
- Severe or worsening hypoxemia.
- Hemodynamic instability.
- Inability to maintain airway patency or protect the airway.
- Transitions of Care Protocol (Transfer or Discharge):
- Conduct a comprehensive medication reconciliation of all newly prescribed sedatives and antipsychotic medications.
- Discontinue antipsychotics and sedatives prior to or at the time of transfer or hospital discharge unless a clear, documented ongoing psychiatric or medical indication is established.
Practice Guidelines References
- 2025 Focused Update: Lewis K, et al. Focused update to the clinical practice guidelines for pain, anxiety, agitation/sedation, delirium, immobility, and sleep disruption in adult ICU patients. Crit Care Med. 2025;53:e711-e727. doi:10.1097/CCM.0000000000006574.
- 2018 PADIS Guidelines: Devlin JW, et al. PADIS clinical practice guideline. Crit Care Med. 2018;46:e825-e873.
- CAM-ICU Validation: Ely EW, et al. JAMA. 2001;286:2707-2710.
- ABCDEF Bundle Implementation: Marra A, et al. Crit Care Clin. 2017;33:225-243.